Current and historical daily PE Ratio for BioNTech SE (
XTER:22UA
) from 2020 to Jun 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. BioNTech SE stock (XTER:22UA) PE ratio as of Jun 25 2024 is 170.65.
More Details
BioNTech SE (XTER:22UA) PE Ratio (TTM) Chart
BioNTech SE (XTER:22UA) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 912
- 1
- 2
- 3
- 4
- 5
- 6
- 11
BioNTech SE PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-25 | 175.9 | 2024-04-22 | 178.5 |
2024-06-24 | 175.9 | 2024-04-19 | 176.5 |
2024-06-21 | 171.8 | 2024-04-18 | 175.2 |
2024-06-20 | 174.9 | 2024-04-17 | 175.1 |
2024-06-19 | 174.2 | 2024-04-16 | 177.0 |
2024-06-18 | 176.3 | 2024-04-15 | 178.0 |
2024-06-17 | 180.0 | 2024-04-12 | 175.2 |
2024-06-14 | 190.1 | 2024-04-11 | 177.7 |
2024-06-13 | 194.2 | 2024-04-10 | 178.3 |
2024-06-12 | 197.0 | 2024-04-09 | 180.0 |
2024-06-11 | 197.9 | 2024-04-08 | 179.2 |
2024-06-10 | 197.9 | 2024-04-05 | 179.6 |
2024-06-07 | 204.9 | 2024-04-04 | 182.1 |
2024-06-06 | 204.1 | 2024-04-03 | 183.9 |
2024-06-05 | 201.3 | 2024-04-02 | 185.2 |
2024-06-04 | 200.0 | 2024-03-28 | 187.2 |
2024-06-03 | 205.0 | 2024-03-27 | 22.5 |
2024-05-31 | 200.5 | 2024-03-26 | 22.3 |
2024-05-30 | 186.8 | 2024-03-25 | 22.3 |
2024-05-29 | 185.1 | 2024-03-22 | 22.1 |
2024-05-28 | 188.3 | 2024-03-21 | 22.4 |
2024-05-27 | 195.0 | 2024-03-20 | 21.3 |
2024-05-24 | 190.9 | 2024-03-19 | 22.7 |
2024-05-23 | 202.4 | 2024-03-18 | 22.3 |
2024-05-22 | 200.2 | 2024-03-15 | 22.2 |
2024-05-21 | 182.8 | 2024-03-14 | 22.4 |
2024-05-20 | 181.7 | 2024-03-13 | 22.4 |
2024-05-17 | 183.9 | 2024-03-12 | 23.0 |
2024-05-16 | 186.6 | 2024-03-11 | 23.3 |
2024-05-15 | 184.6 | 2024-03-08 | 21.7 |
2024-05-14 | 186.1 | 2024-03-07 | 21.8 |
2024-05-13 | 186.7 | 2024-03-06 | 22.0 |
2024-05-10 | 187.4 | 2024-03-05 | 21.6 |
2024-05-09 | 188.3 | 2024-03-04 | 21.5 |
2024-05-08 | 183.5 | 2024-03-01 | 22.3 |
2024-05-07 | 185.2 | 2024-02-29 | 21.8 |
2024-05-06 | 185.7 | 2024-02-28 | 22.2 |
2024-05-03 | 187.2 | 2024-02-27 | 22.7 |
2024-05-02 | 186.2 | 2024-02-26 | 22.6 |
2024-04-30 | 181.8 | 2024-02-23 | 22.7 |
2024-04-29 | 182.3 | 2024-02-22 | 22.7 |
2024-04-26 | 179.1 | 2024-02-21 | 22.2 |
2024-04-25 | 175.4 | 2024-02-20 | 22.1 |
2024-04-24 | 179.7 | 2024-02-19 | 22.2 |
2024-04-23 | 180.0 | 2024-02-16 | 22.3 |
BioNTech SE (XTER:22UA) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![BioNTech SE BioNTech SE logo](https://static.gurufocus.com/logos/0C0000BP8E.png?14)
BioNTech SE
ISIN : US09075V1026
Share Class Description:
XTER:22UA: ADRCompare
Compare
Traded in other countries / regions
BNTX.USA22UA.Germany0A3M.UKB1NT34.BrazilBNTX.MexicoBNTX.Austria IPO Date
2020-11-05Description
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.